Threshold’s Glufosfamide Misses Endpoint In Phase III For Refractory Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Final results from separate Phase II first-line pancreatic cancer trial with Lilly’s Gemzar due in third quarter; company had reported “encouraging” top-line data in December.
You may also be interested in...
Threshold Reports Positive Phase II Results For Glufosfamide For Advanced Pancreatic Cancer
Company is exploring next steps for the oncologic in the pancreatic cancer setting while trials are ongoing for other cancers.
Threshold Reports Positive Phase II Results For Glufosfamide For Advanced Pancreatic Cancer
Company is exploring next steps for the oncologic in the pancreatic cancer setting while trials are ongoing for other cancers.
Threshold Reports "Encouraging" Phase II Glufosfamide Data For Use With Gemzar
Initial safety analysis of pancreatic cancer trial shows a "slightly higher" incidence of nephrotoxicity with the combination regimen compared to individual use of either drug.